Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). AIM Vaccine Co's share price for the quarter that ended in Jun. 2026 was HK$1.66. AIM Vaccine Co's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 1,227 Mil. Therefore, AIM Vaccine Co's market cap for the quarter that ended in Jun. 2026 was HK$2,036 Mil.
AIM Vaccine Co's quarterly market cap
declined
from Jun. 2025 (HK$4,587 Mil) to Dec. 2025 (HK$3,937 Mil) and
declined
from Dec. 2025 (HK$3,937 Mil) to Jun. 2026 (HK$2,036 Mil).
AIM Vaccine Co's annual market cap
declined
from Dec. 2023 (HK$9,507 Mil) to Dec. 2024 (HK$7,436 Mil) and
declined
from Dec. 2024 (HK$7,436 Mil) to Dec. 2025 (HK$3,937 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. AIM Vaccine Co's Enterprise Value for Today is HK$4,046 Mil.
AIM Vaccine Co (HKSE:06660) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
AIM Vaccine Co Market Cap Related Terms
AIM Vaccine Co Market Cap Historical Data
* Premium members only.
The historical data trend for AIM Vaccine Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06660 vs VRTX, REGN, MRNA: Market Cap Comparison
For the Biotechnology subindustry, AIM Vaccine Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM Vaccine Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM Vaccine Co's Market Cap distribution charts can be found below:
* The bar in red indicates where AIM Vaccine Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
AIM Vaccine Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM Vaccine Co (HKSE:06660) has a Market Cap of HK$1,993 Mil as of Sep. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on AIM Vaccine Co and its competitors. According to the industry distribution chart, AIM Vaccine Co ranks #554 out of 1419 companies in the Biotechnology industry, placing it in the top 39%.
Is AIM Vaccine Co's Market Cap too high?
AIM Vaccine Co's current Market Cap is HK$1,993 Mil. Based on the distribution chart, AIM Vaccine Co ranks #554 out of 1419 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AIM Vaccine Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM Vaccine Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AIM Vaccine Co ranks #554 out of 1419 companies for Market Cap. This puts AIM Vaccine Co in the upper half of its industry. The industry median Market Cap is 117.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.60, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on AIM Vaccine Co and its competitors. For the Biotechnology industry, the median Market Cap is 117.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AIM Vaccine Co's current Market Cap is HK$1,993 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM Vaccine Co stock overvalued right now?
Based on GuruFocus' analysis, AIM Vaccine Co (HKSE:06660) is currently considered Possible Value Trap. The stock's GF Value™ is HK$4.08, compared to a current price of HK$1.63 — trading 60.2% below its estimated fair value. The current Market Cap is HK$1,993 Mil. AIM Vaccine Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For AIM Vaccine Co (HKSE:06660), the current Market Cap is HK$1,993 Mil as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM Vaccine Co (HKSE:06660) Overvalued in 2026?
Based on GuruFocus' analysis, AIM Vaccine Co stock appears to be undervalued.
The current stock price of HK$1.63 is trading 60.2% below its estimated GF Value™ of HK$4.08.
GuruFocus considers AIM Vaccine Co to be Possible Value Trap.
Key valuation signals for HKSE:06660:
Market Cap: HK$1,993 Mil
GF Value™: HK$4.08 vs. price of HK$1.63 (60.2% below fair value)
No single metric tells the full story. See the HKSE:06660 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM Vaccine Co Ltd is a China-based full-chain vaccine company engaged in the research and development, manufacturing, and commercialization of vaccine products. The company's commercialized products include recombinant HBV vaccines, freeze-dried human rabies vaccines, inactivated HAV vaccines, Group A, C, Y, and W135 meningococcal polysaccharide vaccines, bivalent inactivated HFRS vaccines, and mumps vaccines. The company generates the majority of its revenue from the PRC.
61GF Score
Get the complete analysis for HKSE:06660
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06660 has been successfully added to your 
